The Safety of Artemisinin Derivatives for the Treatment of Malaria in the 2nd or 3rd Trimester of Pregnancy: A Systematic Review and Meta-Analysis
Fig 5
Pooled odds ratio for congenital anomalies after 2-3rd trimester exposures to artemisinins stratified by comparison group.
*McGready 2001 reported multiple types of artemisinin exposures that were combined for this analysis and reported as ACTs (12). ART: artesunate, AL: artemether-lumefantrine, AAP: artesunate- atovaquone proguanil, AS-AQ: artesunate-amodiaquine, Q: quinine, Q+C: quinine+clindamycin, SP: sulfadoxine pyrimethamine, AQ: amodiaquine, SP+AQ: sulfadoxine pyrimethamine amodiaquine, MQ: mefloquine, CD: chlorproguanal-dapsone, RCT: randomized controlled trial, ACT: artemisinin combination therapy, No exp. No exposure to antimalarials.